Pfizer Drug Mycobutin Granted First Mycobacterosis Approval In Japan
This article was originally published in PharmAsia News
Executive Summary
Pfizer announced July 16 that it obtained approval to manufacture and market its mycobacterosis drug Mycobutin (rifabutin). It's the first mycobacterosis drug in Japan. Rifabutin is also indicated to treat non-tuberculosis mycobacteri and multidrug-resistant tuberculosis. The drug is to treat the onset of MAC that is common among HIV carriers. Approved in 35 countries, Pfizer applied for approval with the Ministry of Health, Labor and Welfare last June. In Japan, the tuberculosis rate is 2.6 per 100,000 people, with around 26,000 people diagnosed each year. That's 1.5 time higher than in the UK and 5 times of the U.S. (Click here for more - Japanese language